<DOC>
	<DOCNO>NCT02252705</DOCNO>
	<brief_summary>Prospective multicenter registry include incident patient prevalent patient pretend identify clinical characteristic , treatment trend in-hospital four year follow-up outcome major adverse cardiovascular event ( MACE ) Mexican population well characterize Pulmonary Hypertension .</brief_summary>
	<brief_title>Mexican Registry Pulmonary Hypertension</brief_title>
	<detailed_description>Introduction . Pulmonary hypertension ( PH ) worldwide group vascular disease characterize progressive increase pulmonary vascular resistance pulmonary arterial pressure secondary vascular right ventricular ( RV ) remodeling , RV dysfunction , heart failure syndrome , finally , premature death . In developed country significant medical advance occur last two decade include systematic assessment availability new therapeutic approach . In addition , current registry show new data regard epidemiology , demography , clinical presentation , treatment prognosis . However , evidence come develop country scarce information necessary identify current care population . In hand , high quality clinical registry may help understand knowledge come clinical trial properly apply result reproducible day-to-day clinical practice . The result REMEHIP , registry one-year enrollment four-year follow-up hopefully broad investigator knowledge clinical profile , medical care , therapeutic trend outcome Mexican population well characterize PH . Variables include . In patient : ) date onset symptom , b ) medical history , c ) personal family history , c ) treatment enrollment , ) physical examination , ) WHO function class , e ) six-minute walk distance , f ) ECG , g ) chest x-ray , h ) echocardiogram , ) pulmonary function test , j ) V/Q lung scan pulmonary angiography , and/or pulmonary angiotomography k ) right heart catheterization , whenever possible indicated acute vasodilator challenge 11 , 12 , l ) biomarkers : troponin I ( TnI ) , brain natriuretic peptide ( BNP ) , D - dimer ( DD ) , INR , n ) current treatment , ) in-hospital follow - outcome , p ) MACE . Visit office . Data collect first outcome update follow-up expect PH symptom , functional class ( WHO ) , current treatment , dose , compliance , collateral effect concomitant medication , weight , blood pressure , heart respiratory rate , biomarkers , possible feasible ; patient oral anticoagulation INR record visit . Visits accord standard health care center , general make least one every six month . Sites . In center ( outcome treatment tertiary center ) , investigator expertise experience diagnosis , stratification treatment patient PH involve . Centers without expertise , facility diagnosis , stratification ( six-minute walk distance , pulmonary function test , V/Q lung scan pulmonary angiography , right heart catheterization , biomarkers ) include , long adhere protocol . Quality Criteria . Following criterion use improve quality data : ) standardize definition , data report ; b ) tool fast feedback ; c ) meeting among principal investigator steer committee , least one per year ; ) ethic procedure review ; e ) electronic , simple accessible data collection ; f ) rigorous center selection base investigator expertise and/or facility resource ) ; g ) consecutive patient enrollment obtain representative sample ; h ) random center audit ; ) centralize data statistical analysis ; j ) report data consistent conclusion ; k ) transparency fund publication . Furthermore , quality registry also measure number publication presentation national international meeting previously do . Data collection . Electronic database 178 variable include among others , data onset symptom , medical history , personal family history , physical examination , six - minute walk distance , treatment , ECG , chest x-ray , echocardiogram , pulmonary function test , V/Q lung scan , pulmonary angiography , right heart catheterization , acute vasodilator challenge , biomarkers ( follow - ) MACE . Statistics . Differences continuous variable normal distribution examine Student 's test . The test Wilcoxon rank sum use continuous variable fail normality test . To analyze categorical variable X2 use Fisher 's exact test Yates correction . A two-tailed test p value &lt; 0.05 consider statistically significant . Logistic regression analysis use select independent predictor variable univariate regression analysis obtain p value &lt; 0.01 . To avoid confusion , relationship historical variable atherosclerosis cardiovascular event examine logistic regression multivariate analysis . Cox proportional risk multivariate model ass relationship variable . Kaplan-Meier survival curve Cox proportional risk model use adjust survival analysis . A p value &lt; 0.05 consider statistically significant . Data express percentage , mean , standard deviation , odds ratio CI .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<criteria>Patients older 2 year : ) diagnosis PH ( PAH RHC ) , b ) Groups I IV Severe pulmonary function abnormality ( vital capacity &lt; 60 % predict , FEV1 &lt; 50 % predict ) Abnormal pulmonary capillary wedge pressure ( &gt; 15 mmHg ) Refusal participate .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Pulmonary arterial hypertension</keyword>
	<keyword>Mortality</keyword>
	<keyword>Survival</keyword>
</DOC>